Pangaea Oncology signs agreement with Qiagen for the development of technology and joint tasks in the segment of molecular diagnostics in oncology
Pangaea Oncology firma un acuerdo con Qiagen para el desarrollo de tecnología y de tareas conjuntas en el segmento de diagnóstico molecular en oncología
Intel ID : 259979
Relevant Documents
| Notice / Relevant Fact | 09 Apr 2018 | Pangaea_Oncology_Hecho_Relevane_2018.pdf | ES |
|
| Intel ID | 259979 | ||
| Value | ND | ||
| Native Currency | Euro (EUR) | ||
|
Financial Data - Pangaea Oncology
(31 Dec 2022) |
Revenue: EUR 7,09m | ||
| Date |
 |
||
| Country |  |
||
| Region | |||
| Continent | |
||
| Geography | |
||
| Subsector (Old TTR Sectors) |
|
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
15.06.01 Colleges & Universities 15 Consumer Products & Services / 15.06 Education & Training Services |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.